{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-021961","form_type":"8-K","ticker":"CING","cik":"0001862150","company_name":"Cingulate Inc.","filed_at":"2022-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.497934+00:00","generated_at":"2026-06-24T01:08:12.983174+00:00","sec_items":["1.01","2.02","2.03","5.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cingulate Q2 net loss $4M, secures $5M insider debt, adds ADHD expert to board","bullets":["Q2 2022 net loss $4.0M (vs $1.4M Q2 2021); six-month net loss $9.0M (vs $2.8M).","Cash $8.2M at June 30, 2022, down from $16.5M Dec 2021; expects to fund through Q1 2023.","Secured $5M unsecured debt from Werth Family Investment at 15% interest, due 2025; quarterly call option from Apr 2023.","Appointed Scott Applebaum to board; brings 10+ years ADHD expertise from Shire (Adderall XR, Vyvanse).","CTx-1301 Phase 3 pediatric trial dosing H2 2022, results H2 2023; company needs ~$16.5M additional capital for NDA."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-021961","json":"https://secwatch.observer/filing/0001493152-22-021961.json","markdown":"https://secwatch.observer/filing/0001493152-22-021961.md","text":"https://secwatch.observer/filing/0001493152-22-021961.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1862150/000149315222021961/0001493152-22-021961-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1862150/000149315222021961/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T01:08:12.983174+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b07d71ba82","claim":"Scott Applebaum was appointed as Class III Director at Cingulate Inc..","evidence_excerpt":"On August 9, 2022, the Board, upon the recommendation of the Nominating and Corporate Governance Committee, expanded the size of the Board to eight directors and appointed Scott Applebaum as a Class III director to serve until the Company’s 2024 annual meeting of stockholders.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1862150/000149315222021961/0001493152-22-021961-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}